These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 6722846)

  • 41. Preliminary study of pirmenol in the treatment of ventricular arrhythmias.
    Gimeno Gascon JV; Algarra Vidal FJ
    Am J Cardiol; 1987 Jun; 59(16):53H. PubMed ID: 3591713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Electrophysiological effects of flecainide on stimulus-inducible ventricular tachycardia].
    Breithardt G; Borggrefe M; Yeh HL; Seipel L
    Z Kardiol; 1982 Apr; 71(4):278-83. PubMed ID: 7090468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical usefulness of flecainide acetate in the treatment of paroxysmal supraventricular arrhythmias.
    Camm AJ; Hellestrand KJ; Nathan AW; Bexton RS
    Drugs; 1985; 29 Suppl 4():7-13. PubMed ID: 4006783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flecainide: a new class Ic antidysrhythmic.
    Smith GH
    Drug Intell Clin Pharm; 1985 Oct; 19(10):703-7. PubMed ID: 3902429
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
    Boriani G; Capucci A; Strocchi E; Calliva R; Santarelli A; Biffi M; Magnani B
    Int J Clin Pharmacol Res; 1993; 13(4):211-9. PubMed ID: 8150547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Flecainide: a new antiarrhythmic drug.
    Med Lett Drugs Ther; 1986 Feb; 28(707):19-20. PubMed ID: 3951388
    [No Abstract]   [Full Text] [Related]  

  • 47. [Effect of intravenous flecainide in the treatment of acute ventricular arrhythmia].
    Aliot E; Baille N; Zannad F; Gilgenkrantz JM
    Ann Cardiol Angeiol (Paris); 1983 Oct; 32(6):417-23. PubMed ID: 6666988
    [No Abstract]   [Full Text] [Related]  

  • 48. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death.
    Reid PR; Griffith LS; Platia EV; Ord SE
    Am J Cardiol; 1984 Feb; 53(5):108B-111B. PubMed ID: 6695814
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Flecainide-induced aggravation of ventricular arrhythmias.
    Wehr M; Noll B; Krappe J
    Am J Cardiol; 1985 Jun; 55(13 Pt 1):1643-4. PubMed ID: 4003313
    [No Abstract]   [Full Text] [Related]  

  • 50. [Propafenone and flecainide in the therapy of ventricular arrhythmias].
    Paperini L; Davini A; Lattanzi F; Topi A; Reisenhofer B; Squarcini G; Paci A; Topi PL
    Minerva Cardioangiol; 1995 Oct; 43(10):449-57. PubMed ID: 8819814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Holmes B; Heel RC
    Drugs; 1985 Jan; 29(1):1-33. PubMed ID: 3882390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multiple comparison of several antiarrhythmic agents by acute oral drug testing in patients with chronic ventricular arrhythmias.
    Facchini M; Bonazzi O; Priori SG; Varisco T; Zuanetti G; Schwartz PJ
    Eur Heart J; 1988 May; 9(5):462-70. PubMed ID: 3402461
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide.
    Morganroth J; Anderson JL; Gentzkow GD
    J Am Coll Cardiol; 1986 Sep; 8(3):607-15. PubMed ID: 3745706
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative multicenter clinical study of flecainide and amiodarone in the treatment of ventricular arrhythmias associated with chronic Chagas cardiopathy].
    Rosenbaum M; Posse R; Sgammini H; Núñez Burgos J; Chiale PA; Pastori JD; González Zuelgaray J; Brunetto JF; Califano JE
    Arch Inst Cardiol Mex; 1987; 57(4):325-30. PubMed ID: 2445316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram.
    Morganroth J; Horowitz LN
    Am J Cardiol; 1984 Feb; 53(5):89B-94B. PubMed ID: 6695821
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
    Priori SG; Bonazzi O; Facchini M; Varisco T; Schwartz PJ
    Am J Cardiol; 1987 Nov; 60(13):1068-72. PubMed ID: 3118693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Flecainide: a new antiarrhythmic drug.
    Mueller RA; Baur HR
    Clin Cardiol; 1986 Jan; 9(1):1-5. PubMed ID: 3510788
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical experience with lorcainide (R 15 889), a new anti-arrhythmic drug.
    Kesteloot H; Stroobandt R
    Arch Int Pharmacodyn Ther; 1977 Dec; 230(2):225-34. PubMed ID: 603318
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia.
    van der Werf C; Kannankeril PJ; Sacher F; Krahn AD; Viskin S; Leenhardt A; Shimizu W; Sumitomo N; Fish FA; Bhuiyan ZA; Willems AR; van der Veen MJ; Watanabe H; Laborderie J; Haïssaguerre M; Knollmann BC; Wilde AA
    J Am Coll Cardiol; 2011 May; 57(22):2244-54. PubMed ID: 21616285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of flecainide acetate for refractory junctional tachycardias in children with the Wolff-Parkinson-White syndrome.
    Ward DE; Jones S; Shinebourne EA
    Am J Cardiol; 1986 Apr; 57(10):787-90. PubMed ID: 3962866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.